2019 WHA Resolution on improving the transparency of markets for medicines, vaccines, and other health products

72nd WHA

Used as precedent

access to health products, pharmaceutical transparency

Not­ing the impor­tance of both pub­lic- and pri­vate-sec­tor fund­ing for research and devel­op­ment of health prod­ucts, and seek­ing to improve the trans­parency of such fund­ing across the value chainSeek­ing to pro­gres­sively enhance the pub­licly avail­able infor­ma­tion on inputs across the value chain of health prod­ucts, the pub­lic report­ing of the rel­e­vant patents and their sta­tus, and the avail­abil­ity of infor­ma­tion on the patents land­scape cov­er­ing a par­tic­u­lar health prod­uct as well as its mar­ket­ing approval sta­tus1. URGES Mem­ber States in accor­dance with their national and regional legal frame­works and con­texts:
(1) to take appro­pri­ate mea­sures to pub­licly share infor­ma­tion on the net prices2 of health prod­ucts;
(2) to take the nec­es­sary steps, as appro­pri­ate, to sup­port dis­sem­i­na­tion and enhanced avail­abil­ity of, and access to, aggre­gated results data and, if already pub­licly avail­able or vol­un­tar­ily pro­vided, costs from human sub­ject clin­i­cal tri­als regard­less of out­comes or whether the results will sup­port an appli­ca­tion for mar­ket­ing approval, while ensur­ing patient con­fi­den­tial­ity;
(3) to work col­lab­o­ra­tively to improve the report­ing of infor­ma­tion by sup­pli­ers on reg­is­tered health prod­ucts, such as reports on sales rev­enues, prices, units sold, mar­ket­ing costs, and sub­si­dies and incen­tives;
(4) to facil­i­tate improved pub­lic report­ing of patent sta­tus infor­ma­tion and the mar­ket­ing approval sta­tus of health prod­ucts;
(5) to improve national capac­i­ties, includ­ing through inter­na­tional coop­er­a­tion and open and col­lab­o­ra­tive research and devel­op­ment and pro­duc­tion of health prod­ucts, espe­cially in devel­op­ing coun­tries and low- and mid­dle-income coun­tries (LMICs), includ­ing health prod­ucts for the dis­eases that pri­mar­ily affect them, as well as for prod­uct selec­tion, cost-effec­tive pro­cure­ment, qual­ity assur­ance, and sup­ply chain man­age­ment